Inhibikase Therapeutics (IKT) Invested Capital (2020 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Invested Capital for 6 consecutive years, with $72.9 million as the latest value for Q3 2025.
- On a quarterly basis, Invested Capital rose 19015.9% to $72.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $72.9 million, a 19015.9% increase, with the full-year FY2024 number at $95.0 million, up 736.08% from a year prior.
- Invested Capital was $72.9 million for Q3 2025 at Inhibikase Therapeutics, down from $80.1 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $95.0 million in Q4 2024 to a low of -$385381.0 in Q3 2024.
- A 5-year average of $34.9 million and a median of $25.4 million in 2023 define the central range for Invested Capital.
- Peak YoY movement for Invested Capital: crashed 102.54% in 2024, then soared 19015.9% in 2025.
- Inhibikase Therapeutics' Invested Capital stood at $38.4 million in 2021, then crashed by 44.86% to $21.2 million in 2022, then tumbled by 46.37% to $11.4 million in 2023, then soared by 736.08% to $95.0 million in 2024, then dropped by 23.25% to $72.9 million in 2025.
- Per Business Quant, the three most recent readings for IKT's Invested Capital are $72.9 million (Q3 2025), $80.1 million (Q2 2025), and $85.8 million (Q1 2025).